Nouveau labo! Je cherche des étudiant(e)s gradué(e)s voulant travailler dans le domaine de l'épissage de l'ARN en #cancer et #immunologie. New lab! I'm looking for grad students interested in #RNAsplicing in #cancer and #immunology mqvlab.com @jrRNAscientists

RT @BiologyOpen@mstdn.science Our sister journals Dev_journal J_Cell_Sci J_Exp_Biol & DMM_Journal offer Travelling Fellowships of up to £3,000 to #biology #PhD students & #Postdocs wishing to make collaborative visits to other laboratories. Next application deadline is 5 (1/2)

RT @iRnaCosi@genomic.social Thrilled to announce our upcoming journal club, May 2, 11:30am EDT (15:30GMT). Dr. Matvei Khoroshkin, postdoc in genophoria lab at UCSF, will present results from their preprint on the discovery of RNA structural (1/2)

RT @Suig@mstdn.party #NPR should run their own #Mastodon instance as should every other serious news outfit. This bullshit where supposedly serious news organizations should have to capitulate to the whims of some narcissistic billionaire or corrupt government is (1/2)

The NIH will be taking comments from the postdoc community over the next few days. Topics of high importance are on the agenda: - Role, duration, structure, and value of the postdoc - International trainee concerns - Compensation and benefits - Job security, career (1/2)

RT @mbonsma@mastodon.social A major escarpment access in #Hamilton is closing on short notice. Should you be worried about increased congestion because of detours? Surprisingly, probably not! A thread about "traffic evaporation", the cool cousin of induced demand. (1/2)

RT @snolen@journa.host Maybe you've heard about Trikafta, the 'miracle' drug that has transformed life for people with cystic fibrosis in North America and Europe? It costs $322,000 a year, and patients take it for life. Turns out the drug isn't available for CF (1/3)

patients anywhere in the developing world. And they say that's on purpose: that the maker, Vertex Pharmaceuticals, is deliberately obstructing access so as to be able to maintain that price (2/3)

RT @cyrilpedia@qoto.org My latest clinical pipeline column for NatureMedicine is out today. It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody for relapsed or refractory follicular (1/2)

RT @vscooper@mstdn.science Just (re)discovered Casey Greene's super "preprint similarity search tool". It did a great job for our recent #preprint. It uses a language learning model to find like #publications to help you pick your target (1/2)